14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -5.676 13 days ( 42.75 % )
Last Price $3.87 -10.00 %
High/ Low $3.78 - $4.15 -21.96%
Chg 7 Days -23.21 % $5.04 $3.87
Chg 30 Days -43.59 % $6.86 $3.87
Chg 12 mos -33.51 % $5.82 $3.87
Trend - 3 mos -10.08 % Width: 113.85 %
Trend - 12 mos 24.08 % Width: 247.83 %
Pred. range - 3 mos $3.31 - $7.07 -14.53 % - 82.79 %
Pred. range - 12 mos $3.06 - $10.64 -20.96 % - 174.93 %
Short MA avg 3 mos Sell Apr 01, 2024 - 19 days
Long MA avg 3 mos Sell Mar 28, 2024 - 20 days
Short/Long MA avg 3 mos Sell Mar 25, 2024 - 23 days
Short MA avg 12 mos Sell Mar 21, 2024 - 25 days
Long MA avg 12 mos Sell Apr 16, 2024 - 8 days
Short/Long MA avg 12 mos Buy Dec 14, 2023 - 91 days
Pivot Short Sell Mar 07, 2024 - 35 days
Bollinger Buy Apr 11, 2024 - 11 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Fate Therapeutics

Fate Therapeutics Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul... FATE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT